Skip to content

Psilocybin: all studies

Page 367 of 440: studies 3,661 to 3,670 of 4,392, newest first. Back to the psilocybin overview

Research

Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists

Journal of Medicinal Chemistry April 22, 2024 Karla Frydenvang, Emil Märcher-Rørsted, Anders A. Jensen et al. 7 citations

Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clinical trials for a range of psychiatric indications, including depression, anxiety, and substance abuse disorder. These compounds are characterized by broad pharmacological activity profiles, and while the acute mind-altering effects can be ascribed...

DOI: 10.1021/acs.jmedchem.4c00082 (opens in new tab) Pharmacology 5-HT Receptor Structure–activity relationship Serotonin agonist +1

The selective 5-HT2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents

bioRxiv Preprint Server April 19, 2024 Anders A. Jensen, Cláudia R. Cecchi, Meghan Hibicke et al. preprint

Psychedelic-assisted psychotherapy has over the last decade emerged as a promising treatment strategy for mental health disease, and the therapeutic potential in classical psychedelics such as psilocybin, LSD and 5-MeO-DMT is presently being pursued in a plethora of clinical trials. However, the resurgent interest in the drugs as therapeutics has also prompted a search for novel agents with...

A dual-receptor model of serotonergic psychedelics

bioRxiv (Cold Spring Harbor Laboratory) April 15, 2024 Arthur Juliani, Veronica Chelu, Laura Graesser et al. 4 citations preprint

Abstract Serotonergic psychedelics have been identified as promising next-generation therapeutic agents in the treatment of mood and anxiety disorders. While their efficacy has been increasingly validated, the mechanism by which they exert a therapeutic effect is still debated. A popular theoretical account is that excessive 5-HT2a agonism disrupts cortical dynamics, relaxing the precision of...

Psychedelics and the ‘inner healer’: Myth or mechanism?

Journal of Psychopharmacology April 12, 2024 Joseph Peill, Miriam Marguilho, David Erritzøe et al. 16 citations

Background: Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic drug-using cultures. The ‘inner healer’ refers to the belief that psychedelic compounds, plants or concoctions have an intrinsically regenerative action on the mind and brain, analogous to intrinsic healing mechanisms within the physical body, for example, after sickness or injury....

DOI: 10.1177/02698811241239206 (opens in new tab) Telos Automatic Psychedelic-therapy Natural-healing +2

Who will staff the psychedelic resurgence?

Open Access Government April 9, 2024 Erika Dyck

Who will staff the psychedelic resurgence? Erika Dyck, Professor and Canada Research Chair in History of Health & Social Justice from the University of Saskatchewan, provides an intriguing answer to this question. On 6th February 2024, a research team at Le Grau-du-Roi Hospital in the south of France, led by addictologist Amandine Luquiens, put their first subject through a clinical trial with...

Cultivation, chemistry, and genome of Psilocybe zapotecorum

Journal of Psychedelic Studies April 5, 2024 Dusty R. Miller, Jordan Taylor Jacobs, Alan Rockefeller et al. 7 citations

Abstract Psilocybe zapotecorum is a strongly blue-bruising psilocybin mushroom used by indigenous groups in southeastern Mexico and beyond. While this species has a rich history of ceremonial use, research into its chemistry and genetics has been limited. Herein, we report on mushroom morphology, cultivation parameters, chemical profile, and the full genome sequence of P. zapotecorum . First,...

MDMA-gestützte Therapie

Nervenheilkunde April 1, 2024 Laura Bechtold, Dimitris Repantis

ZUSAMMENFASSUNGNeben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung,...

Psychedelic Renaissance: Evidence and Culture

Psychiatric News April 1, 2024 Adrian Preda

Back to table of contents Previous article Next article Editor's DeskFull AccessPsychedelic Renaissance: Evidence and CultureAdrian Preda, M.D.Adrian Preda, M.D.Published Online:21 Mar 2024https://doi.org/10.1176/appi.pn.2024.04.4.39The ebb and flow of societal beliefs often resemble a pendulum's swing, oscillating between acceptance and rejection. This phenomenon is not confined to the annals...

Magic mushroom and zebrafish: A new recipe?

Lab Animal April 1, 2024 Robert Gerlai 1 citation

No, we are not talking about a new dish for dinner, but a study representing an emerging research field. Psilocybin research is gaining momentum, and zebrafish behavioral neuroscience research has been exponentially expanding. At the intersection of these two research fields is a recent paper that utilized high-tech video-tracking to detect behavioral changes induced by this psychoactive drug...

Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika

Fortschritte der Neurologie · Psychiatrie April 1, 2024 Stefan Borgwardt, Tomislav Majić, Mihai Avram et al.

Klassische Psychedelika wie Psilocybin, Lysergsäurediethylamid (LSD), Ayahuasca oder 5-Methoxy-Dimethyltryptamin (5-MeO-DMT) stehen wieder vermehrt im Fokus des psychiatrisch-psychotherapeutischen und neurowissenschaftlichen Interesses. Dies ist vor allem auf aktuelle klinische Studien zurückzuführen, die einen möglichen therapeutischen Nutzen von Psychedelika in der Behandlung verschiedener...